Currently, the National Comprehensive Cancer Network (NCCN) recommends plasma-based molecular testing as part of broad molecular profiling in all patients with non-squamous NSCLC at the time of diagnosis, if there is insufficient tissue to test all relevant targets, (EGFR, ALK, ROS1, BRAF, MET, NTRK and RET) [31]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.